Comparative Pharmacology
Head-to-head clinical analysis: IODOTOPE versus SODIUM PHOSPHATE P 32.
Peer-Reviewed Evidence
Head-to-head clinical analysis: IODOTOPE versus SODIUM PHOSPHATE P 32.
IODOTOPE vs SODIUM PHOSPHATE P 32
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Iodine-131 is taken up by the thyroid gland and emits beta particles and gamma rays, causing destruction of thyroid tissue via radiation-induced cell death.
Sodium phosphate P 32 is a radioactive isotope that emits beta particles, causing ionization and subsequent cell death, particularly in rapidly dividing cells. It is incorporated into DNA and RNA, concentrating in tissues with high metabolic activity such as bone marrow and neoplastic cells.
For thyroid ablation: 3.7-5.55 MBq (100-150 μCi) orally as a single dose. For hyperthyroidism: 185-555 MBq (5-15 mCi) orally as a single dose.
Intravenous administration: 1.5 mCi (55.5 MBq) per 70 kg body weight, single dose. For polycythemia vera, oral dose: 3-5 mCi (111-185 MBq) as a single dose. Frequency is one-time or as needed based on response.
None Documented
None Documented
Terminal half-life is approximately 120-140 days for total body iodine, but the effective half-life for therapeutic use is 8-13 days due to biological turnover in the thyroid. For diagnostic use, effective half-life is 1-2 days.
Terminal elimination half-life: 14.3 days (range 13-16 days). Clinically relevant for bone marrow suppression monitoring; cumulative effect over multiple doses.
Primarily renal: >90% excreted in urine as iodide. Fecal excretion is negligible (<2%).
Renal: ~40% within 24 hours via glomerular filtration; Fecal: ~60% over 1-2 weeks as unabsorbed or secreted into bile. Total elimination approaches 100% after 2 weeks.
Category C
Category C
Radiopharmaceutical
Radiopharmaceutical